Akebia Therapeutics Inc (AKBA)
1.335
0.00 (0.00%)
USD |
NASDAQ |
Apr 26, 16:00
1.335
0.00 (0.00%)
After-Hours: 19:38
Akebia Therapeutics Debt to Equity Ratio: -1.134 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
December 31, 2023 | -1.134 |
September 30, 2023 | -1.081 |
June 30, 2023 | -1.585 |
March 31, 2023 | -3.504 |
December 31, 2022 | 12.63 |
September 30, 2022 | 4.760 |
June 30, 2022 | 1.576 |
March 31, 2022 | 3.747 |
December 31, 2021 | 1.318 |
September 30, 2021 | 0.7089 |
June 30, 2021 | 0.555 |
March 31, 2021 | 0.4517 |
December 31, 2020 | 0.3892 |
September 30, 2020 | 0.2409 |
June 30, 2020 | 0.2062 |
Date | Value |
---|---|
March 31, 2020 | 0.1919 |
December 31, 2019 | 0.192 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.0236 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.00 |
December 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.504
Minimum
Mar 2023
12.63
Maximum
Dec 2022
1.035
Average
0.2409
Median
Sep 2020
Debt to Equity Ratio Benchmarks
Ocugen Inc | 0.069 |
Aquestive Therapeutics Inc | -0.2585 |
SELLAS Life Sciences Group Inc | -- |
Protagonist Therapeutics Inc | 0.00 |
Stoke Therapeutics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 241.70M |
Total Liabilities (Quarterly) | 272.29M |
Shareholders Equity (Quarterly) | -30.58M |
Current Ratio | 1.183 |
Net Debt Paydown Yield | 2.59% |